In Silico Evaluation of the Antibacterial and Antiviral Potential of Nusbiarylin Derivatives

Ognjen Milić; Nikola Nedeljković; Miloš Nikolić

doi:10.5937/arhfarm76-67266

Ognjen Milić University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical Technology and Cosmetology, Belgrade, Serbia
Nikola Nedeljković University of Kragujevac - Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia
Miloš Nikolić University of Kragujevac - Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia

DOI: https://doi.org/10.5937/arhfarm76-67266

Keywords: molecular docking, nusbiarylin derivatives, drug-likeness analysis, RNA polymerase, HCV RNAP, dual inhibitors

Abstract

Antimicrobial resistance and chronic viral infections are major challenges in contemporary medicine. This in silico study evaluated the dual inhibitory potential of 16 designed nusbiarylin derivatives against two clinically relevant enzymatic targets: Escherichia coli (E. coli) RNA polymerase (RNAP) and hepatitis C virus RNA-dependent RNA polymerase (HCV RNAP). Semi-flexible molecular docking was performed using AutoDock Vina. Six compounds – 5, 6, 7, 8, 15, and 16 – showed the most favorable dual inhibitory potential, forming key hydrogen bonds with Ser642 of E. coli RNAP and with Tyr477 and Arg422 of HCV RNAP, along with significant hydrophobic interactions. The presence of cyano or nitroso groups as hydrogen bond acceptors, and sulfonyl or sulfoxide groups contributing π-S interactions, were identified as key determinants of binding affinity at both targets. These findings support further experimental evaluation of nusbiarylin derivatives as potential dual-activity antibacterial and antiviral agents.

References

Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: An Overview. Int J Environ Res Public Health. 2013;10(12):6235–54.

Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89–96.

Waheed Y, Bhatti A, Ashraf M. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs. Infect Genet Evol. 2013;14:247–57.

Sutherland C, Murakami KS. An Introduction to the Structure and Function of the Catalytic Core Enzyme of Escherichia coli RNA Polymerase. EcoSal Plus. 2018;8(1). doi: 10.1128/ecosalplus.ESP-0004-2018.

Sesmero E, Thorpe IF. Using the Hepatitis C Virus RNA-Dependent RNA Polymerase as a Model to Understand Viral Polymerase Structure, Function and Dynamics. Viruses. 2015;7(7):3974–94.

Bae B, Nayak D, Ray A, Mustaev A, Landick R, Darst SA. CBR antimicrobials inhibit RNA polymerase via at least two bridge-helix cap-mediated effects on nucleotide addition. Proc Natl Acad Sci U S A. 2015;112(31):E4178–87.

Wei Y, Li J, Qing J, Huang M, Wu M, Gao F, et al. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking. PLoS One. 2016;11(2):e0148181.

Selami E, Berivan S, Yusuf S. Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study. J Biomol Struct Dyn. 2020;38(2):573–80.

Yang X, Luo MJ, Yeung ACM, Lewis PJ, Chan PKS, Ip M, et al. First-In-Class Inhibitor of Ribosomal RNA Synthesis with Antimicrobial Activity against Staphylococcus aureus. Biochemistry. 2017;56(38):5049–52.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.

Egan WJ, Merz KM Jr, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43:3867–77.

Molinspiration Cheminformatics [Internet]. Molinspiration; 2026 [cited 2026 April 18]. Available from: https://www.molinspiration.com/cgi-bin/properties.

Buntrock RE. ChemOffice Ultra 7.0. J Chem Inf Comput Sci. 2002;42(6):1505–6.

Feng Y, Degen D, Wang X, Gigliotti M, Liu S, Zhang Y, et al. Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles. Structure. 2015;23(8):1470–81.

Biswal BK, Cherney MM, Wang M, Chan L, Yannopoulos CG, Bilimoria D, et al. Crystal Structures of the RNA-dependent RNAP Genotype 2a of Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms of Inhibition by Non-nucleoside Inhibitors. J Biol Chem. 2005;280(18):18202–10.

Discovery Studio Visualizer. Version 17.2. [Internet]. Dassault Systèmes; 2016 [cited 2026 May 13]. Available from: https://www.3ds.com/products/biovia/discovery-studio/.

Qiu Y, Chan ST, Lin L, Shek TL, Tsang TF, Zhang Y, et al. Nusbiarylins, a new class of antimicrobial agents: Rational design of bacterial transcription inhibitors targeting the interaction between the NusB and NusE proteins. Bioorg Chem. 2019;92:103203.

Qiu Y, Chu AJ, Tsang TF, Zheng Y, Lam NM, Li KSL, et al. Synthesis and biological evaluation of nusbiarylin derivatives as bacterial rRNA synthesis inhibitor with potent antimicrobial activity against MRSA and VRSA. Bioorg Chem. 2022;124:105863.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.

Wang M, Ng KKS, Cherney MM, Chan L, Yannopoulos CG, Bedard J, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase: crystal structures and mechanism of inhibition. J Biol Chem. 2003;278(18):16149–58.